Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “GD2 Antibody (Naxitamab)”

2 trials

Showing 2 of 2 results

Not applicableLooking for participantsNCT06574698
What this trial is testing

Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

Who this might be right for
NeuroblastomaGD2 Antibody (Naxitamab)
Guangzhou Women and Children's Medical Center 64
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07537400
What this trial is testing

Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5

Who this might be right for
High-Risk Neuroblastoma
Shaare Zedek Medical Center 10

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation